Depo-Provera debate revs up at FDA.
D000328:Adult; D000818:Animals; D002273:Carcinogens; D003271:Contraceptive Agents, Female; D004285:Dogs; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007390:International Agencies; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D002273:Carcinogens; D003271:Contraceptive Agents, Female; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone